newsfilter
← Latest News
GlobeNewswire·

Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01

STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01,